Indication intelligence, analysis and sector perception

bluebird bio (BLUE) proposes 9.09 M share offering priced at $55.00

May 19, 2020 6:34am

BLUE priced offering at $55.00

Monday BLUE closed up +$0.48 to $57.14 ... a minor float to the downside?

Seeking proceeds of $500 M excluding any exercise of the underwriter's option (1.3 M shares)

Blue has commenced an underwritten public offering of $500 million of its common stock. blue also intends to grant the underwriters a 30-day option to purchase up to an additional 1.363 million shares offered in the public offering.

Goldman Sachs & Co. LLC, BofA Securities and Cowen are acting as joint book-running managers of the proposed offering.

The Bottom line: Based on Friday's stock closing price of $56.66 and Monday's $57.14, the offering will be for about 9.09 million shares, or about 12.7% of the current shares outstanding. All of the shares would be sold by the company.

BLUE has dropped -35.8% over the past three months ...

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.